<scp>COVID</scp> severity test (<scp>CoST</scp> sensor)—An electrochemical immunosensing approach to stratify disease severity

With the evolution of COVID-19 pandemic, there is now a need for point-of-care devices quantification disease biomarkers toward severity assessment. Disease progression has been determined as multifactor phenomenon and can be treated based on host immune response within each individual. CoST an electrochemical immunosensor device that determine through multiplex measurement spike protein, nucleocapsid D-dimer, IL-2R from 100 μL plasma samples few minutes. The limit detection was found to 3 ng/mL 21 S N proteins whereas D-dimer it 0.0006 0.242 ng/mL, respectively. Cross-reactivity all studied <20%. Inter intra-assay variability sensor less than <15% confirming its ability detect target biomarker in body fluids. In addition, this platform also tested quantify four 40 patient predict index. A significant difference observed between healthy with p-value 0.0002 <0.0001 other COST used point care assess at clinical sites. This modified impact wide range indications where prognostic monitoring critical modulating therapy.